<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103943</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2021-05</org_study_id>
    <nct_id>NCT05103943</nct_id>
  </id_info>
  <brief_title>Amyloidosis TTR Flow Reserve Evaluation</brief_title>
  <acronym>AMYTRE</acronym>
  <official_title>Amyloidosis TTR Flow Reserve Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anginal symptoms and signs of ischemia have been reported in some patients with cardiac&#xD;
      amyloidosis (TTR) without obstructive epicardial coronary artery disease (CAD).&#xD;
&#xD;
      It was found that coronary microvascular dysfunction was highly prevalent in subjects with&#xD;
      cardiac amyloidosis, even in the absence of epicardial CAD. The investigators found lower&#xD;
      stress and rest myocardial blood flow (MBF) and lower myocardial flow reserve (MFR) in their&#xD;
      cardiac PET (Positron emission tomography) study (13N), including 21 patients.&#xD;
&#xD;
      The advances in SPECT technology including cadmium zinc telluride (CZT) detectors allow to&#xD;
      evaluate the MBF and MFR estimation by SPECT as shown in both experimental animal models and&#xD;
      also in clinical studies with comparison to PET.&#xD;
&#xD;
      SPECT is more widely available than cardiac PET. Thus, the investigators would like:&#xD;
&#xD;
        1. to confirm the results of Dorbala et al using SPECT, and&#xD;
&#xD;
        2. to go further with evaluation of the effect of Tafamidis on microvascular dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of Stress and Rest Myocardial Blood Flow</measure>
    <time_frame>Month 24</time_frame>
    <description>Difference of Stress and Rest Myocardial Blood Flow (mL/min/g) at baseline and after 24 months of treatments, assessed by dynamic SPECT (regional and global left ventricle measurements)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ratio of Stress Myocardial Blood Flow/ Rest Myocardial Blood Flow</measure>
    <time_frame>Month 24</time_frame>
    <description>Difference of Myocardial Flow Reserve (ie ratio of Stress Myocardial Blood Flow/ Rest Myocardial Blood Flow) at baseline and after 24 months of treatments, assessed by dynamic SPECT (regional and global left ventricle measurements)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number or participants with stress reduction</measure>
    <time_frame>baseline</time_frame>
    <description>Stress assessed by dynamic SPECT (regional and global left ventricle measurements), in comparison to &quot;normal&quot; values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number or participants with rest MBF (myocardial blood flow) reduction</measure>
    <time_frame>baseline</time_frame>
    <description>Rest Myocardial Blood Flow (mL/min/g) assessed by dynamic SPECT (regional and global left ventricle measurements), in comparison to &quot;normal&quot; values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ratio of Stress Myocardial Blood Flow/ Rest Myocardial Blood Flow</measure>
    <time_frame>Baseline</time_frame>
    <description>Myocardial Flow Reserve (ie ratio of Stress Myocardial Blood Flow/ Rest Myocardial Blood Flow) assessed by dynamic SPECT (regional and global left ventricle measurements) in comparison to &quot;normal&quot; values</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Amyloid Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>SPECT MPI (myocardial perfusion imaging) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the SPECT MPI protocol will be modified to evaluated MBF and MFR. This modification will result in no added radiation; the radiopharmaceutical dose will still be the same compared to a standard MPI protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SPECT MPI</intervention_name>
    <description>SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR</description>
    <arm_group_label>SPECT MPI (myocardial perfusion imaging) Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged from 18 to 90 years&#xD;
&#xD;
          -  Understanding and speaking French&#xD;
&#xD;
          -  With TTR amyloid cardiomyopathy (ATTRxt or ATTRm) confirmed by the association of&#xD;
             heart failure, syncope or bradyarrhythmia, with electrocardiogram and/or magnetic&#xD;
             resonance imaging (CMR) suggesting/indicating cardiac amyloid, grade 2 or 3 99mTc- PYP&#xD;
             or bone scintigraphy and negative biological findings (i.e. serum immunofixation,&#xD;
             urine immunofixation, serum free light chain assay); or, if one of those criteria is&#xD;
             not met, presence of amyloid deposits on analysis of biopsy specimens obtained from&#xD;
             cardiac and non-cardiac sites (17-19),&#xD;
&#xD;
          -  Intention to treat (Tafamidis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure not due to transthyretin amyloid cardiomyopathy;&#xD;
&#xD;
          -  New York Heart Association (NYHA) class IV heart failure.&#xD;
&#xD;
          -  The presence of light-chain amyloidosis;&#xD;
&#xD;
          -  A history of liver or heart transplantation;&#xD;
&#xD;
          -  An estimated glomerular filtration rate lower than 25 mL per minute per 1.73 m2 of&#xD;
             bodysurface area (Cockcroft).&#xD;
&#xD;
          -  Liver transaminase levels exceeding two times the upper limit of the normal range;&#xD;
&#xD;
          -  Severe malnutrition as defined by a modified body-mass index (mBMI) of less than 600,&#xD;
             calculated as the serum albumin level in grams per litter multiplied by the&#xD;
             conventional BMI (the weight in kilograms divided by the square of the height in&#xD;
             meters);&#xD;
&#xD;
          -  Patients receiving concurrent treatment with nonsteroidal anti-inflammatory drugs,&#xD;
             tauroursodeoxycholate, doxycycline, calcium-channel blockers, or digitalis;&#xD;
&#xD;
          -  Previous treatment with tafamidis or patisaran;&#xD;
&#xD;
          -  Ticagrelor treatment&#xD;
&#xD;
          -  Previous CAD, severe epicardial stenosis with revascularization or ticagrelor&#xD;
             treatment, coronary artery bypass grafting, myocardial infarction;&#xD;
&#xD;
          -  Contra-indications to pharmacological stress testing MPI: severe hypotension (&lt; 90&#xD;
             mmHg of Systolic arterial pressure), atrioventricular block 2nd or 3rd grade, carotid&#xD;
             stenosis (unilateral &gt;70%, bilateral &gt;50%);&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Protected adults&#xD;
&#xD;
          -  Other study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu BAILLY, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR d'ORLEANS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>+33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'ANNGERS</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Loïc BIERRE, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR d'Orleans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthieu BAILLY, Dr</last_name>
      <email>matthieu.bailly@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de TOURS</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne BERNARD, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R, Foster C, Hanley M, Di Carli MF, Falk R. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014 Aug;2(4):358-67. doi: 10.1016/j.jchf.2014.03.009. Epub 2014 Jul 9.</citation>
    <PMID>25023822</PMID>
  </reference>
  <reference>
    <citation>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.</citation>
    <PMID>30145929</PMID>
  </reference>
  <reference>
    <citation>Al Suwaidi J, Velianou JL, Gertz MA, Cannon RO 3rd, Higano ST, Holmes DR Jr, Lerman A. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999 Dec 7;131(11):838-41.</citation>
    <PMID>10610629</PMID>
  </reference>
  <reference>
    <citation>Ogawa H, Mizuno Y, Ohkawara S, Tsujita K, Ando Y, Yoshinaga M, Yasue H. Cardiac amyloidosis presenting as microvascular angina--a case report. Angiology. 2001 Apr;52(4):273-8.</citation>
    <PMID>11330510</PMID>
  </reference>
  <reference>
    <citation>Whitaker DC, Tungekar MF, Dussek JE. Angina with a normal coronary angiogram caused by amyloidosis. Heart. 2004 Sep;90(9):e54.</citation>
    <PMID>15310723</PMID>
  </reference>
  <reference>
    <citation>Nam MC, Nel K, Senior R, Greaves K. Abnormal Myocardial Blood Flow Reserve Observed in Cardiac Amyloidosis. J Cardiovasc Ultrasound. 2016 Mar;24(1):64-7. doi: 10.4250/jcu.2016.24.1.64. Epub 2016 Mar 24.</citation>
    <PMID>27081447</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tafamidis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

